Geode Capital Management LLC Decreases Stock Holdings in Bruker Corporation $BRKR

Geode Capital Management LLC trimmed its position in shares of Bruker Corporation (NASDAQ:BRKR) by 0.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,072,846 shares of the medical research company’s stock after selling 12,218 shares during the period. Geode Capital Management LLC’s holdings in Bruker were worth $97,673,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BRKR. Royal Bank of Canada increased its holdings in shares of Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock valued at $5,148,000 after acquiring an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Bruker during the first quarter valued at about $262,000. Goldman Sachs Group Inc. increased its holdings in shares of Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after acquiring an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock valued at $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 6,008 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BRKR shares. Stifel Nicolaus set a $45.00 price objective on shares of Bruker in a report on Friday, May 8th. UBS Group upped their price objective on shares of Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Wolfe Research started coverage on shares of Bruker in a report on Monday, June 1st. They set a “peer perform” rating on the stock. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group set a $50.00 price objective on shares of Bruker in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.54.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $56.39 on Friday. The business’s 50 day moving average price is $42.57 and its 200 day moving average price is $43.45. The firm has a market cap of $8.58 billion, a P/E ratio of -234.96, a P/E/G ratio of 1.81 and a beta of 1.31. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.54. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be given a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio is currently -83.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.